Regeneron gets FDA green light for first Ebola treatment Inmazeb
The Food and Drug Administration has cleared Regeneron’s Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients.
"Today's action demonstrates the FDA's ongoing commitment to responding to public health threats—both domestically and abroad—on the basis of science and data," said FDA commissioner Stephen Hahn. "This approval was made possible because of our steadfast dedication to facilitate the development of safe and effective treatments for infectious diseases as part of our vital public health mission."
Zaire ebolavirus, commonly known as Ebola virus, is one of four Ebolavirus species that can cause a potentially fatal human disease. Ebola virus is transmitted through direct contact with blood, body fluids and tissues of infected people or wild animals, as well as with surfaces and materials, such as bedding and clothing, contaminated with these fluids. Individuals who provide care for people with Ebola virus, including health care workers who do not use correct infection control precautions, are at the highest risk for infection.
Inmazeb targets the glycoprotein that is on the surface of Ebola virus. Glycoprotein attaches to the cell receptor and fuses the viral and host cell membranes allowing the virus to enter the cell. The three antibodies that make up Inmazeb can bind to this glycoprotein simultaneously and block attachment and entry of the virus.
"Today's approval highlights the importance of international collaboration in the fight against Ebola virus," said John Farley, director of the Office of Infectious Diseases in the FDA's Center for Drug Evaluation and Research. "The urgent need for advanced therapies to combat this infectious disease is clear, and today's action is a significant step forward in that effort."